Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
W. Taylor Kimberly, MD PhD is a stroke and critical care neurologist in the Department of Neurology. He serves as the Associate Director of the MGH Neuroscience Intensive Care Unit and Associate Chief of the Division of Neurocritical Care and Emergency Neurology.
Clinically, he primarily cares for patients in the Neuroscience ICU as part of an integrated and multi-disciplinary team, coordinating care with Neurosurgery and Neuroendovascular specialists. He sees Neuro ICU patients in follow-up in outpatient clinic as part of the Neurorecovery clinical team. He serves on several hospital-based and national committees that focus on clinical guideline development and care improvement.
Dr. Kimberly's research group is located in the Center for Genomic Medicine (Kimberly Lab), and studies metabolomic and neuroimaging biomarkers of subarachnoid hemorrhage, stroke and cerebral edema. The goal of his research is to identify novel pathways and candidate therapeutic targets for the treatment of acute brain injury. Dr. Kimberly has co-led multi-site, randomized, placebo-controlled trials in the prevention of brain edema, and currently co-leads an international phase 3 trial evaluating the safety and efficacy of intravenous glyburide for the prevention of brain edema after large hemispheric stroke.
View my most recent research
Dr. Kimberly's laboratory is devoted to the study of secondary brain injury after stroke. His research group (Kimberly Lab) develops novel tools, including neuroimaging analysis, metabolomics and proteomics, to identify clinically relevant markers of stroke. Promising candidates may become diagnostic or prognostic biomarkers. However, the primary goal of the laboratory is to leverage biomarkers to study the biological and pathological events following acute stroke and to bring new treatments to patients through multicenter clinical trials.
View my most recent publications at PubMed
A phase 2 clinical trial of a drug that may alleviate brain swelling – a dangerous stroke complication – suggests the treatment may help reduce brain injury and death, and information from the study will help design the phase 3 trial.
Back to Top